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Abstract Type I interferon (IFN-α/β) is a fundamental antiviral defense mechanism. Mouse 
models have been pivotal to understanding the role of IFN-α/β in immunity, although validation 
of these findings in humans has been limited. We investigated a previously healthy child with 
fatal encephalitis following inoculation of the live-attenuated measles, mumps and rubella 
(MMR) vaccine. By targeted resequencing we identified a homozygous mutation in the high-
affinity interferon-α/β receptor (IFNAR2) in the proband, as well as a newborn sibling, that 
rendered cells unresponsive to IFN-α/β. Reconstitution of the proband’s cells with wild-type 
IFNAR2 restored IFN-α/β responsiveness and control of IFN-attenuated viruses. Despite the 
severe outcome of systemic live-vaccine challenge, the proband had previously shown no 
evidence of heightened susceptibility to respiratory viral pathogens. The phenotype of IFNAR2 
deficiency, together with similar findings in STAT2 deficient patients, supports an essential but 
narrow role for IFN-α/β in human antiviral immunity. 
 
Summary: Human IFNAR2 deficiency causes fatal susceptibility to live viral vaccines, revealing 
a vital but narrow nonredundant role for IFN-α/β in viral immunity. 
Introduction: Understanding the concerted antiviral immune response is an important goal for 
immunologists, vaccinologists and virologists.  In the current paradigm, viral sensing leads to the 
induction of an antiviral program that is powerfully amplified and propagated by innate 
interferons (IFNs α/β and ). These soluble cytokines induce an antiviral, antiproliferative state 
by signaling at specific cell-surface receptors, inducing the expression of hundreds of interferon-
stimulated genes (ISGs) to inhibit viral replication (1). Furthermore, IFNs contribute to the 
recruitment and activation of both innate and adaptive immune effectors (2, 3). Whilst responses 
to IFN- are limited by receptor expression to the mucosal epithelium, all nucleated cells 
respond to IFN-α/β. This potent systemic antiviral defense exerts ongoing selective pressure, as 
reflected by the fact that most pathogenic viruses have evolved mechanisms of IFN evasion (4).  
 
Mouse knockout models have been pivotal to our understanding of IFN-α/β biology (5-8). Mice 
lacking the ubiquitously expressed receptor for IFN-α/β (Ifnar), or downstream signaling 
components (tyrosine kinase 2 [Tyk2], signal transduction and activator of transcription-1 [Stat1] 
or Stat2) manifest complex defects in viral resistance and immune homeostasis (9). As a result, 
IFN-α/β has been used in humans to treat diverse pathological states including chronic viral 
infection, multiple sclerosis and cancer (10). However, evidence for the nonredundant role of 
IFN-α/β in human antiviral immunity is scant. No human defects in IFNAR are reported; 
currently recognised primary immunodeficiencies (PIDs) that affect downstream signaling do so 
either nonspecifically (TYK2, STAT1) (11, 12), due to their involvement in other critical 
signaling pathways, or incompletely (STAT2) (13). Nonetheless, human STAT2 deficiency 
results in a narrow but severe phenotype of innate antiviral immunodeficiency, particularly 
following systemic challenge with live-viral vaccines such as measles, mumps and rubella 
(MMR) (13).  
 
Results: We evaluated a 13-month old infant who developed severe, prolonged and ultimately 
fatal encephalitis, as a complication of MMR vaccination (Fig. 1A and supplementary case 
report). There was clear evidence of sustained replication of vaccine viruses, as well as human 
herpes virus 6 (HHV6), in systemic and brain samples (Table S1), despite an appropriate 
serological response to MMR (Table S2). Given the clinical similarities to STAT2-deficiency, in 
a patient with normal adaptive immune parameters (Table S3), we suspected a PID involving the 
innate antiviral response. We therefore examined the ability of patient dermal fibroblasts to 
control the replication of attenuated viruses deleted for specific IFN-α/β antagonists (14, 15), and 
observed that, unlike control cells, they supported the formation of large plaques (Fig. 1B). 
Patient cells were also unable to develop an antiviral state in response to exogenous IFN-α, 
showing unhindered wild-type viral replication as compared with significant inhibition in 
controls (Fig. 1C). In contrast, IFN-γ treatment was capable of inducing a partial antiviral state in 
patient and control cells (Fig. S1). These findings implied an IFN-α/β signaling defect. Indeed, 
IFN-α failed to induce the expression of classical antiviral gene products in patient cells (Fig. 
1D). To determine the degree to which IFN-α/β signaling was impaired, we measured the global 
transcriptional response of fibroblasts to IFN-α, IFN-β and IFN-γ by whole genome microarray. 
There were no differences in basal transcriptional profile between the patient and three 
independent controls, however we observed a striking failure of transcriptional responses to IFN-
α/β in the patient (Fig. 1E). Of 230 and 374 probes differentially expressed in response to IFN-α 
or IFN-β respectively (224 overlapping), none were induced in the patient (datasets S1 and S2). 
In contrast, IFN-γ responses were preserved (Fig. 1E, dataset S3).  
  
We sought to localize this profound defect by examining successive phosphorylation steps within 
the IFN-α/β signaling pathway. IFNAR is a heterodimer composed of low affinity (IFNAR1) and 
high affinity (IFNAR2) subunits, which are respectively associated with the kinases TYK2 and 
JAK1 (16). In normal cells, IFNAR ligation by IFN-α/β results in reciprocal 
transphosphorylation of JAK1 and TYK2. These phosphorylate STAT1 and STAT2, which 
associate with IRF9 to form Interferon-Stimulated Gene Factor 3 (ISGF3) and thereby effect 
gene transcription (1) (Fig. 2A). We observed complete failure of tyrosine phosphorylation of 
JAK1, TYK2, or STAT 1/2 in patient cells exposed to IFN-α (Fig. 2B) or IFN-β (Fig. S2).  By 
contrast, phosphorylation of JAK1 and STAT1 following IFN-γ treatment was normal (Fig. 2C). 
These differential effects on JAK1/STAT1 phosphorylation localized the signaling defect 
proximally, to IFNAR itself (Fig. 2A).  
 
To identify the putative genomic variant, we first sequenced IFNAR1 and IFNAR2 in 
complementary DNA. There were no variants in IFNAR1 and corresponding protein expression 
was normal (Fig. 3C).  In contrast, we identified a single rare variant in IFNAR2, namely a 
single-base deletion in exon 5 (c.A311del; Ref. ENST00000342136, Fig. 3A). This variant 
proved to be homozygous in genomic DNA of the proband as well as a newborn sibling, and 
heterozygous in both parents, but was absent from a healthy control sequenced in parallel and 
from public databases of genomic variation such as dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP/) and Ensembl release 78 (http://www.ensembl.org). 
A311 is highly conserved in bovine to rodent to ape orthologues of IFNAR2 and is present in all 
IFNAR2 transcript variants. The c.A311del variant introduces a frameshift substitution of glycine 
in place of glutamic acid at position 104, generating a downstream premature stop codon 
(pE104fs110X). IFNAR2 has three protein isoforms, generated by exon skipping, alternative 
splicing, and differential use of polyadenylation sites (16) (Fig. 3B), although only one 
(IFNAR2c) is functional (17). The c.A311del variant is predicted to truncate all isoforms at the 
first N-terminal fibronectin III domain (Fig. 3B). In keeping with a loss of full length protein, we 
could not detect IFNAR2 by immunoblot with a C-terminal antibody (Fig. 3C and Fig. S3) and 
in this respect the patient cells resembled the IFNAR2-deficient sarcoma cell line U5A (18) (Fig. 
S4).  
 
To prove definitively that the homozygous c.A311del IFNAR2 variant was responsible for the 
functional defect in IFN signaling, we transduced fibroblasts from the proband with wild-type 
IFNAR2 (IFNAR2c) (Fig. 4A). IFNAR2c complementation restored responsiveness to IFN-α as 
measured by STAT1 tyrosine phosphorylation (Fig. 4B), ISG induction (Fig. 4C) and reduction 
in WT viral protein expression (Fig. 4E; see also Fig. 1C for control responses). Importantly, it 
also reinstated the ability to control the replication of IFN-sensitive viruses (Fig. 4D).  
 
Discussion: This previously unreported PID, IFNAR2 deficiency, directly informs our 
understanding of the role of IFN-α/β in human antiviral immunity. Despite a profound defect in 
IFN-α/β signaling, conferring serious viral susceptibility in vitro and in vivo, there was no 
evidence of clinically relevant vulnerability to commonly encountered viruses prior to the MMR-
related illness in the proband. The precise contribution of each attenuated vaccine virus to the 
final illness is difficult to quantify but both mumps and rubella were detected in brain biopsy 
more than 7 weeks after vaccination. HHV6 was also detected, but HHV6 latency is ubiquitous 
by the first years of life, and its role as a pathogen or commensal in the CNS is not fully resolved 
(19). Whether HHV6 was directly involved in neuropathology, or acting as a bystander - as has 
been reported with other neurotropic viral illness (20) - is unclear. However, susceptibility to 
neurotropic herpesviruses is a recognized feature of human defects in innate viral sensing (21, 
22), possibly reflecting the tissue-specific importance of IFN-α/β in CNS antiviral immunity 
(23). Intriguingly, the control of systemic cytomegalovirus (CMV) replication in the IFNAR2 
proband indicated the presence of additional effective means of herpesvirus surveillance. This 
reflects the situation in STAT2-deficient patients, where individuals controlled Epstein-Barr 
virus (EBV) and varicella zoster virus (VZV), as well as various respiratory viruses (13), despite 
severe illness arising from live-vaccine challenge. These data, which contrast starkly with the 
mouse models (5, 8), imply unappreciated redundancy in IFN-α/β-mediated antiviral defense. 
The discordance between immunological and clinical infection phenotypes also recalls other 
PIDs affecting innate immune recognition and/or signaling, such as deficiencies of IRAK4 (24) 
and MyD88 (25). These generate narrow bacterial susceptibility profiles in humans (26), as a 
consequence of signaling network redundancy and/or complementation by adaptive immunity. 
Indeed, the capacity of IFN-γ to generate an antiviral state in IFNAR2 deficient cells suggests a 
potentially important therapeutic avenue for patients with IFN-α/β signaling defects. The 
apparent absence of a functional T cell defect in patients with IFNAR2 or STAT2-deficiency 
implies that the murine paradigm, in which aspects of T cell activation and maintenance are 
attributed to IFN-α/β signaling (9), does not translate into a clinically relevant phenotype in 
humans. Similarly, other important homeostatic abnormalities reported in Ifnar-/- mice, such as 
impaired myelopoiesis or defects in thymic T cell development (16), are not a feature of human 
deficiencies of IFNAR2 or STAT2, presumably as a consequence of divergent species evolution 
(27).  
 
The susceptibility to systemic live-attenuated viruses caused by defects of IFN-α/β response is 
striking. Serial passage in nonhuman cells (28) may result in the loss of IFN-evasion genes 
among other undefined mechanisms of attenuation (29). Such attenuation is rendered inoperative 
in the IFN-α/β deficient host, revealing the viruses’ underlying potential for widespread 
dissemination and pathogenicity (30). This behavior recalls the ability of another live-attenuated 
vaccine, Bacille Calmette-Guérin (BCG), to reveal otherwise cryptic immune defects in 
Mendelian Susceptibility to Mycobacterial Disease (31). Importantly, the systemic route of 
vaccine administration evades tissue-specific innate mechanisms that might otherwise 
complement the lack of IFN-α/β, such as mucosal IFN- (32). As a result, the kinetics and 
multiplicity of infection likely differ significantly from natural exposure at mucosal surfaces. 
Our data suggest that pathological dissemination of live-viral vaccines in previously healthy 
individuals must be assumed to reflect a lesion in the IFN-α/β pathway until proven otherwise. 
 
 
Materials and Methods:  
Clinical samples were obtained and testing undertaken following written informed consent from 
parents in accordance with the Declaration of Helsinki and with local Research Ethics 
Committee approval. Dermal fibroblasts from patient II.1 and healthy controls were obtained by 
standard methods and cultured in Dulbecco’s Modified Eagle’s Medium supplemented by 10% 
fetal calf serum and 1% penicillin/streptomycin (DMEM-10). Peripheral blood mononuclear 
cells were isolated by density gradient centrifugation from patient II.2 and healthy controls and 
cultured in RMPI medium supplemented by 10% fetal calf serum and 1% penicillin/streptomycin 
(RPMI-10). The IFNAR2-deficient human sarcoma cell line U5A (18) (a kind gift from 
Professor Steve Goodbourn) was cultured in DMEM-10. Diagnostic immunology and virology 
analyses were performed in accredited regional diagnostic laboratories to standard protocols.  
 
Lentiviral transduction 
Lentiviral particles were prepared by AMS Bio (Abingdon, UK). Supplied were target particles 
encoding the full length open reading frame of human IFNAR2 transcript variant 1 
(NM_207585) under the control of the constitutive promoter EF1a, with a GFP-Puromycin 
selection marker under an RSV promoter, as well as null control particles lacking the IFNAR2 
target, but containing the vector backbone. Patient dermal fibroblasts were spinoculated in 6-well 
plates for 1.5 h at 2000 rpm, with target or null control viral particles, at multiplicity of infection 
(MOI) 5 in a total volume of 0.5mL DMEM-10 containing hexadimethrine bromide (Polybrene, 
8 g/mL, Sigma). Cells were rested in virus-containing medium for 8 h then incubated in fresh 
DMEM10 until 48 h, when they were selected in DMEM-10 containing 0.5 g/mL puromycin 
(Sigma). Puromycin-containing medium was refreshed every 72 h.  
 
Viruses and interferons  
Viruses, plaque assay methodology and immunofluorescence have been described previously 
(13). Interferon- (Intron-A, Schering-Plough, New Jersey, USA), interferon- (Avonex, Biogen 
Idec, Maidenhead, UK) and interferon- (Immunikin, Boehringer Ingelheim, Ingelheim am 
Rhein, Germany) were used at 1000 IU/mL unless otherwise stated.  
 
Immunoblotting 
Confluent monolayers of dermal fibroblasts or 2x106 PBMC in 24-well plates were washed in 
phosphate buffered saline (PBS) and lysed on ice in lysis buffer (20 mM Tris HCl, pH 7.4, 150 
mM NaCl, 1% Triton X-100, 5 mM EDTA) containing 100 mM dithiothreitol (DTT, Sigma-
Aldrich, Missouri, USA), 1 x protease inhibitor cocktail (Roche, Basel, Switzerland) with 
phosphatase inhibitors (10mM sodium fluoride and 1mM sodium orthovanadate, Sigma-Aldrich) 
and 1 x NuPAGE® Loading Buffer (Life Technologies, Paisley, UK). Lysates were heated to 
90oC for 20 min prior to 4-12% Tris-Glycine polyacrylamide gel electrophoresis (Novonex®, 
Life Technologies, Paisley, UK) in 1 x sodium dodecyl sulfate (SDS) NuPAGE® MOPS 
Running Buffer (Life Technologies). 5 L of Prestained Protein Ladder (Thermo Scientific, Life 
Technologies, Paisley, UK) was used as a size marker. Proteins were transferred to 0.45 m 
polyvinyl difluoride (PVDF) membranes (Thermo Scientific Pierce, Life Technologies, Paisley, 
UK) in NuPAGE® Tris-Glycine Transfer Buffer. Membranes were blocked for 30 min in 5% 
bovine serum albumin or 5% milk in tris-buffered saline with 0.1% Tween (TBS-T) prior to 
immunostaining by standard methods. The following anti-human antibodies together with 
appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies were used for 
immunostaining (all rabbit unless otherwise stated): Sheep IFNAR2 C-terminal (AF7014, R&D 
Systems, Minnesota, USA); Goat ISG56/IFIT1 (sc-82946, Santa Cruz, Texas, USA); MXA 
(Mx1/2/3) (sc-34128, Santa-Cruz); IFNAR1 C-terminal (EP899Y, Abcam, Cambridge, UK); 
STAT2 (07-140, Millipore, Massachusetts, USA); Phospho-STAT2 (Tyr690, No. 4441); TYK2 
(No. 9132); Phospho-TYK2 (Tyr1054/1055, No. 9321); JAK1 (No. 3332); Phospho-JAK1 
(Tyr1022/1023, No. 3331); STAT1 (No. 9172); Phospho-STAT1 (Tyr701, Clone D4A7, No. 
7649); GAPDH (D16H11, No. 5174), all Cell-Signaling Technologies, Massachusetts, USA. 
Membranes were washed in TBS-T and developed with ImmobilonTM Western 
Chemiluminescent HRP substrate (Millipore). Visual spectrum and chemiluminescent images 
were captured on a G:BOX Chemi (Syngene, Hyarana, India) CCD camera using Genesnap 
software (Syngene). Composite light/chemiluminescent images were generated without 
manipulation and exported in TIFF format.  
 
Mutation screening 
Complementary DNA was synthesized from purified RNA as previously described (13).  
IFNAR1 and IFNAR2 were PCR-amplified from the cDNA with specific primers designed in 
Primer3web version 4.0.0 (http://bioinfo.ut.ee/primer3/). Primer sequences are available on 
request. Capillary sequencing was performed according to standard methods. Sequences were 
aligned with the consensus coding sequence (human genome assembly 38) in nucleotide BLAST 
(http://blast.ncbi.nlm.nih.gov/blast/).  
 
Microarray analysis 
Patient dermal fibroblasts in triplicate wells and control fibroblasts from three independent 
donors in 24-well plates were treated with 1000 IU/mL IFN-, IFN-, IFN- or medium alone 
for 10 h. RNA was isolated by using the ReliaPrep RNA Cell Miniprep System (Promega) 
according to manufacturers’ instructions. Microarrays were performed by ServiceXS Ltd. 
(Leiden, Netherlands). 200 ng of total RNA were used to synthesize biotinylated cRNA target, 
which was subject to QC checks, then hybridized (750 ng cRNA per sample) to Illumina HT-12 
v4 Expression Bead Chips (Illumina Inc. San Diego, USA). Data from two Illumina HT-12 v4 
Expression Bead Chips per sample were background corrected in Illumina Beadstudio with 
further analysis carried out using the Lumi and Limma Bioconductor packages in R (33, 34). 
Normalization of background corrected data was applied through variance stabilizing 
transformation (VST) and robust spline normalization (RSN) in Lumi (35). Testing for 
differential expression between IFN-treated patient and control cells was done with linear models 
and empirical Bayesian statistics, utilizing a multi-level experiment approach through Limma. 
Gene lists for each comparison were generated. Data plots were created using the ggplot2 library 
in R. 
 
Statistical analysis 
Differential gene expression was considered significant if the Benjamini-Hochberg false 
discovery rate (FDR) adjusted P value was < 0.01, and the absolute fold change in expression 
level was ≥ 2 (i.e. 2 fold increase or decrease in expression from baseline). 
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 Figure Legends 
Figure 1. Failure of IFN-α/β antiviral response. (A) Meningoencephalitis on cortical biopsy. 
Cortical inflammatory cell nodular infiltrate (left) with marked microglial activation (CD45 
staining, middle) and patchy dural inflammation (right). Scale bars 100m (B) Patient fibroblasts 
supported the formation of large plaques by parainfluenza 5 and Bunyamwera viruses deleted for 
IFN-α/β antagonists (PIV5C, BUNNSs).  Scale bar 1cm (C) Failure of IFN-α to inhibit wild-
type (WT) PIV5 replication in patient fibroblasts, revealed by immunofluorescence staining of 
viral antigen. Scale bars 50m.  (D)  Immunoblot showing absence of antiviral protein (MXA 
and IFIT1/ISG56) induction by IFN-α (representative of n=3 experiments). (E) Absent 
transcriptional response to IFN-α and IFN-β but preserved IFN- response in patient cells, 
assessed by microarray; red dots represent significantly differentially expressed probes ( 2-fold, 
adj. P<0.01, n=3 replicates). Exact P values are reported in supplemental datasets S1-3. Patient = 
patient II.1 (see Figure 3). 
Figure 2. Absence of IFN-α/β signaling but preserved IFN- signaling. (A) Schematic of 
IFN-α/β and IFN- signal transduction. (B) Absent tyrosine phosphorylation of 
TYK2/JAK1/STAT1/STAT2 in response to IFN-α. (C) Normal tyrosine phosphorylation of 
JAK1/STAT1 in response to IFN- (C). Data are representative of n=3 experiments. Patient = 
patient II.1 (see Figure 3). 
Figure 3. Autosomal recessive IFNAR2-deficiency. (A) Capillary sequencing of IFNAR2 
revealed variant c.A311del was homozygous in patient II.1, resulting in a frameshift mutation 
p.E104fs110X, heterozygous in both parents, and homozygous in a newborn sibling, II.2. (B) 
A311del is predicted to truncate all protein isoforms of IFNAR2 at the first N-terminal 
extracellular domain (ECD). (C) Absent IFNAR2 expression in fibroblasts of the proband by 
immunoblot with an antibody against C-terminal IFNAR2 (representative of n=3 experiments).  
 Figure 4. IFNAR2 complementation restores IFN-α/β responses. (A) Stable expression of 
WT IFNAR2 or null control by lentiviral transduction in patient fibroblasts restored: (B) STAT1 
tyrosine phosphorylation; (C) ISG induction (representative immunoblots of n=3 experiments); 
(D) Control of IFN-attenuated viruses parainfluenza 5 VC (PIV5VC) and Edmonton strain 
measles (MeV) in plaque assays; and (E) overnight IFN-α inhibition of Enders mumps vaccine 
(MuV), PIV3 and PIV5 by immunofluorescent detection of viral protein. Scale bars 200m, 
Patient = patient II.1. 
 
